Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 197

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study

Open access
Anderson, Garnet L., McIntosh, Martin, Wu, Lieling, Barnett, Matt, Goodman, Gary, Thorpe, Jason D., Bergan, Lindsay, Thornquist, Mark D., Scholler, Nathalie, Kim, Nam, O'Briant, Kathy, Drescher, Charles, Urban, Nicole·2010·JNCI: Journal of the National Cancer Institute

Abstract

BACKGROUND: CA125, human epididymis protein 4 (HE4), mesothelin, B7-H4, decoy receptor 3 (DcR3), and spondin-2 have been identified as potential ovarian cancer biomarkers. Except for CA125, their behavior in the prediagnostic period has not been evaluated. METHODS: Immunoassays were used to determine concentrations of CA125, HE4, mesothelin, B7-H4, DcR3, and spondin-2 proteins in prediagnostic serum specimens (1-11 samples per participant) that were contributed 0-18 years before ovarian cancer diagnosis from 34 patients with ovarian cancer (15 with advanced-stage serous carcinoma) and during a comparable time interval before the reference date from 70 matched control subjects who were participating in the Carotene and Retinol Efficacy Trial. Lowess curves were fit to biomarker levels in cancer patients and control subjects separately to summarize mean levels over time. Receiver operating characteristic curves were plotted, and area-under-the curve (AUC) statistics were computed to summarize the discrimination ability of these biomarkers by time before diagnosis. RESULTS: Smoothed mean concentrations of CA125, HE4, and mesothelin (but not of B7-H4, DcR3, and spondin-2) began to increase (visually) in cancer patients relative to control subjects approximately 3 years before diagnosis but reached detectable elevations only within the final year before diagnosis. In descriptive receiver operating characteristic analyses, the discriminatory power of these biomarkers was limited (AUC statistics range = 0.56-0.75) but showed increasing accuracy with time approaching diagnosis (eg, AUC statistics for CA125 were 0.57, 0.68, and 0.74 for > or = 4, 2-4, and <2 years before diagnosis, respectively). CONCLUSION: Serum concentrations of CA125, HE4, and mesothelin may provide evidence of ovarian cancer 3 years before clinical diagnosis, but the likely lead time associated with these markers appears to be less than 1 year.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djp438

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 197

Metadata

Authors
Anderson, G. L., McIntosh, M., Wu, L., Barnett, M., Goodman, G., Thorpe, J. D., Bergan, L., Thornquist, M. D., Scholler, N., Kim, N., O'Briant, K., Drescher, C., & Urban, N.
Venue
JNCI: Journal of the National Cancer Institute
Published
2010-01-06
Volume
102
Issue
1
Pages
26-38
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2167006237
Cited by
197
References
4
FWCI
26.40
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study. https://app.cochat.ai/papers/10.1093/jnci/djp438
The paper
Anderson, G. L., McIntosh, M., Wu, L., Barnett, M., Goodman, G., Thorpe, J. D., Bergan, L., Thornquist, M. D., Scholler, N., Kim, N., O'Briant, K., Drescher, C., & Urban, N. (2010). Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djp438

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.